SCHEMBL91561

SCHEMBL91561

COc1ccc2c(c1)c(C(=O)Nc1cc(Cl)c(C)cc1Cl)cn2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CREBBP Q92793 1/20 0.48
TP53 P04637 2/20 0.47
ABCG2 Q9UNQ0 1/20 0.46
MAPT P10636 4/20 0.46
POLB P06746 3/20 0.46
MTNR1A P48039 5/20 0.43
MTNR1B P49286 5/20 0.43
NQO2 P16083 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
EPHB3 P54753 1/20 0.42
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91548 0.94 MEN1 (0.48) MEN1KMT2AALDH1A1SMN1; SMN2CREBBP
SCHEMBL93044 0.88 RAB9A (0.46) MEN1KMT2AALDH1A1SMN1; SMN2TP53
SCHEMBL91539 0.84 MAPT (0.42) ALDH1A1SMN1; SMN2TP53MAPTPOLB
SCHEMBL91608 0.83 MAOB (0.54) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL10285849 0.81 RAB9A (0.46) MEN1KMT2AALDH1A1SMN1; SMN2TP53
SCHEMBL5708295 0.80 ITGB1 (0.49) MEN1KMT2AALDH1A1SMN1; SMN2CREBBP
SCHEMBL5708315 0.79 ITGB1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2CREBBP
SCHEMBL93047 0.78 RAB9A (0.43) SMN1; SMN2TP53MAPTPOLBNPC1
SCHEMBL92363 0.77 ITGB1 (0.42) ALDH1A1TP53MAPTPOLBLMNA
SCHEMBL93049 0.77 RAB9A (0.59) MEN1KMT2ASMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 MEN1 4254/4885KMT2A 568/4885ALDH1A1 216/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 MEN1 4337/4885KMT2A 656/4885ALDH1A1 207/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 MEN1 4226/4885KMT2A 881/4885ALDH1A1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.